Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

April 24, 2028

Study Completion Date

June 27, 2029

Conditions

Lung Cancer, Non-Small Cell

Interventions

BIOLOGICAL

Pembrolizumab

Pembrolizumab will be administered.

BIOLOGICAL

Dostarlimab

Dostarlimab will be administered.

DRUG

Pemetrexed+ (carboplatin or cisplatin)

PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.

Trial Locations (1)

GSK Investigational Site, London